Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.6, Iss.5, 1997-05, pp. : 609-614
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Since the discovery of a second isozyme of cyclooxygenase, COX-2, the field of prostaglandin and inflammation research has rapidly developed. It is becoming more evident that inhibition of COX-2 results in the analgesic and anti-inflammatory actions of non-steroidal anti-inflammatory drugs (NSAIDs), and that inhibition of COX-1 results in the adverse side-effects seen with these compounds. The mechanisms causing intestinal ulceration and renal toxicity are being elucidated, and large scale clinical trials with a preferential COX-2 inhibitor, meloxicam, and the first clinical results with highly selective COX-2 inhibitors, such as MK966 and celecoxib, support a superior benefit to risk ratio. In addition, important new areas where COX-2 expression is elevated, such as colonic cancer, have been identified and a role for COX-2 has also been proposed in Alzheimer’s disease. Inhibition of COX-2 for these indications by selective COX-2 inhibitors may provide effective new therapies in the future.
Related content
Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design, Vol. 10, Iss. 6, 2004-02 ,pp. :
Selective inhibitors of cyclooxygenase-2
By Talley J.J.
Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 1, 1997-01 ,pp. :